Semaglutide and Tirzepatide
Over the last 15 years, Semaglutide has been used to treat type 2 diabetes, but has been approved by the FDA to help manage weight loss (along with diet and exercise) in obese or overweight adults.
Semaglutide is injected under the skin with a tiny insulin needle, once weekly at any time of day, with or without food, and should be injected on the same day each week.
Since these medications were initially designed to treat type 2 diabetes, we typically recommend it be taken with our intermittent fasting diet.
Originally approved for diabetic patients, Tirzepatide (brand name Mounjaro) combines a GLP-1 agonist (the same type of medication found in the weight loss drug Semaglutide) with a new medication known as a GIP agonist.
In a recent New England Journal of Medicine study, 91% of patients sustained significant weight loss with Tirzepatide. Read the full article here: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
Tirzepatide is injected under the skin with a tiny insulin needle, once weekly at any time of day, with or without food, and should be injected on the same day each week.